Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
antiaglomerantes: talco, estearato de magnesio, celulosa
Potential candidates People with documented L-carnitine deficiency (rare but does occur, particularly in individuals with certain genetic conditions, kidney disease, or those on dialysis) have a clear medical rationale for L-carnitine supplementation
Instead, it is more appropriate to envision metabolic plasticity regarding uptake of alternative metabolic substrates and promotion of metabolic rewiring as a built-in feature that has evolved to allow cancer cells to constantly adapt to changing intracellular- and extracellular metabolic conditions 2
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
US$ 21.51
US$ 20.25
US$ 29.43
US$ 29.04
US$ 22.71
US$ 27.91
US$ 25.48
US$ 26.15
US$ 21.86
